Available online http://ccforum.com/content/11/3/415 Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal adverse reaction to neuroleptic drugs, including amisulpride [1, 2] . NMS most commonly presents with increased body temperature, muscular rigidity of a 'lead pipe' nature, altered mental status and autonomic dysfunction. Other extrapyramidal movement disorders such as tremor and cogwheel phenomena are also frequently present. The treatment of NMS includes discontinuation of contributing drugs and supportive therapy, but specific treatment with dantrolene, bromocriptine, nondepolarizing neuromuscular paralysis and benzodiazepines, among other such agents, has been reported only anecdotally. A recent analysis of published case reports [3] evaluated the efficacy of dantrolene in NMS; it found that dantrolene, given as monotherapy, might be helpful in managing this syndrome if the premedication was a neuroleptic monotherapy. We present video evidence of the effectiveness of dantrolene in reducing muscular rigidity, tremor and cogwheel phenomena in a patient with NMS.
Amisulpride therapy was initiated in a 79-year-old patient with a schizoaffective disorder. After 10 days the patient became somnolent with a high body temperature (40.3°C), diaphoresis, tachycardia, rigid skeletal muscles of a 'lead pipe' character, cogwheel phenomena and resting tremor (video footage is available in Additional data file 1). Laboratory results revealed creatine kinase to be 15.1 µkat/l and myoglobin to be 8,654 µg/l, indicating rhabdomyolysis. Blood urea nitrogen was 11.6 mmol/l and creatine was 139 µmol/l, indicating renal failure that probably was caused by dehydration. Procalcitonin was within normal limits, excluding infection. A brain computed tomography scan and lumbar puncture findings were normal. NMS caused by treatment with amisulpride was suspected and it was discontinued.
External cooling with sponging and fanning was started. Bromocriptine, a dopamine agonist, was introduced at a dose of 5 mg every 8 hours through a nasogastric tube, but after 1 day there was no clinical improvement and so bromocriptine was withdrawn. Then, 60 mg (1 mg/kg) dantrolene was administered intravenously over 5 min. Muscle rigidity, cogwheel phenomena and tremor disappeared within 10 min (video footage is available in Additional file 2), but they gradually reappeared within an hour. The dantrolene infusion was repeated three times within 12 hours and body temperature gradually decreased to 37.5°C. Bromocriptine therapy was continued two more days. The patient's level of consciousness improved and signs of NMS disappeared during subsequent days.
The diagnosis of NMS in this patient is based on identifying the characteristic clinical manifestations in association with a typical history of therapy with amisulpride, which antagonizes dopaminergic D 2 /D 3 receptor subtypes. The patient also developed renal failure, which may participate in amisulpride accumulation because amisulpride is eliminated unchanged in urine.
Dantrolene might be useful in managing skeletal muscle rigidity because it relaxes skeletal muscles by inhibiting release of calcium from the sarcoplasmic reticulum, thereby reducing actin-myosin contractile activity. In the videos presented (Additional data files 1 and 2) the effect of dantrolene on muscular rigidity of a 'lead pipe' nature, cogwheel phenomena and tremor are clearly visible. However, the usefulness of dantrolene in NMS remains questionable, and this is but one of a number of anecdotal reports. Nevertheless, it offers an additional visual impression of the effectiveness of dantrolene on rigidity and tremor caused by NMS.
To conclude, we speculate that prompt reduction in NMSassociated muscular rigidity by dantrolene contributed to a decrease in body temperature. Our reporting of this case was approved by the Hospital Committee for Medical Ethics (University Medical Centre Ljubljana).
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Video of dantrolene effectiveness on neuroleptic malignant syndrome associated muscular rigidity and tremor
